13) Sun J, Schiffman J, Raghunath A, et al: Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 8: 9, 2008.
17) Levy L, Hill CS: Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17: 41-58, 2006.
18) Wrzesinski SH, Wan YY, Flavell RA: Transforming growth factor-β and the immune response: implications for anticancer therapy. Clin Cancer Res 13: 5262-5270, 2007.
19) Teicher BA: Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 20: 133-143, 2001.
20) Dong M, Blobe GC: Role of transforming growth factor-β in hematologic malignancies. Blood 107: 4589-4596, 2006.
22) Teicher BA: Transforming growth factor-β and the immune response to malignant disease. Clin Cancer Res 13: 6247-6251, 2007.
23) Song B-C, Chung Y-H, Kim JA, et al: Transforming growth factor-β1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 94: 175-180, 2002.
24) Xu WQ, Jiang XC, Zheng L, et al: Expression of TGF-β1, TβR II and Smad4 in colorectal carcinoma. Exp Mol Pathol 82: 284-291, 2007.
25) Arteaga CL: Inhibition of TGFβ signaling in cancer therapy. Curr Opin Genet Dev 16: 30-37, 2006.
26) Galliher AJ, Schiemann WP: β3 integrin and Src facilitate transforming growth factor-β mediated inductionof epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 8:R42, 2006.
27) McKarns SC, Schwartz RH, Kaminski NE: Smad3 is essential for TGF-β1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J Immunol 172: 4275-4284, 2004.
29) Shull MM, Ormsby I, Kier AB, et al: Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359: 693-699, 1992.
30) Kulkarni AB, Huh CG, Becker D, et al: Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90: 770-774, 1993.
31) Gorelik L, Flavell RA: Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12: 171-181, 2000.
32) Lucas P, Kim J-S, Melby SJ, et al: Disruption of T cell homeostasis in mice expressing a T cell-specificdominant negative transforming growth factor β II receptor. J Exp Med 191: 1187-1196, 2000.
33) Classen S, Zander T, Eggle D, et al: Human resting CD4+ T cells are constitutively inhibited by TGFβ under steady-state conditions. J Immunol 178: 6931-6940, 2007.
34) Eisele G, Wischhusen J, Mittelbronn M, et al: TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 129: 2416-2425, 2006.
35) Castriconi R, Cantoni C, Della Chiesa M, et al: Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100: 4120-4125, 2003.
36) Lee JC, Lee KM, Kim DW, et al: Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172: 7335-7340, 2004.
37) Geissmann F, Revy P, Regnault A, et al: TGF-β1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 162: 4567-4575, 1999.
38) Liu VC, Wong LY, Jang T, et al: Tumor evasion of the immune system by converting CD4+CD25+ T cells into CD4+CD25- T regulatory cells: role of tumor-derived TGF-β. J Immunol 178: 2883-2892, 2007.
39) Pyzik M, Piccirillo CA: TGF-β1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. J Leukoc Biol 82: 335-346, 2007.
40) Nam JS, Terabe M, Kang MJ, et al: Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68: 3915-3923, 2008.
41) Nam JS, Terabe M, Mamura M, et al: An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 68: 3835-3843, 2008.
42) Morris JC, Shapiro GI, Tan AR, et al: Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). 2008 ASCO Annual Meeting Proccedings: 489s.
43) Uhl M, Aulwurm S, Wischhusen J, et al: SD-208, a novel transforming growth factor β receptor I kinaseinhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64: 7954-7961, 2004.
44) Ge R, Rajeev V, Ray P, et al: Inhibition of growth and metastasis of mouse mammary carcinoma by selective nhibitor of transforming growth factor-β type I receptor kinase in vivo. Clin Cancer Res 12: 4315-3430, 2006.
45) Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, et al: SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 3: 737-745, 2004.
46) Suzuki E, Kim S, Cheung HK, et al: A novel small-molecule inhibitor of transforming growth factor β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 67: 2351-2359, 2007.
48) Fakhrai H, Mantil JC, Liu L, et al: Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine inpatients with advanced glioma. Cancer Gene Ther 13: 1052-1060, 2006.
49) Moore LD, Isayeva T, Siegal GP, et al: Silencing of transforming growth factor-β1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo. Clin Cancer Res 14: 4961-4970, 2008.
51) Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000.
54) Jung YJ, Isaacs JS, Lee S, et al: IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17: 2115-2117, 2003.
69) Lonnroth C, Andersson M, Arvidsson A, et al: Preoperative treatment with a non-steroidal antiinflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 8: 5, 2008.
76) Oyama T, Ran S, Ishida T, et al: Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J Immunol 160: 1224-1232, 1998.
79) Belotti D, Paganoni P, Manenti L, et al: Matrix metalloproteinase (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 63: 5224-5229, 2003.
88) Krockenberger M, Dombrowski Y, Weilder C, et al: Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol 180: 7338-7348, 2008.